Tamoxifen and CYP2D6: A Contradiction of Data

  • Hertz D
  • McLeod H
  • Irvin W
70Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

Abstract

Tamoxifen is an effective antiestrogen used in the treatment of hormone receptor-positive breast cancer. Bioconversion of tamoxifen to endoxifen, its most abundant active metabolite, is primarily dependent on the activity of cytochrome P450 2D6 (CYP2D6), which is highly polymorphic. Over 20 published studies have reported on the potential association between CYP2D6 polymorphism and tamoxifen treatment outcome, with highly inconsistent results. The purpose of this review is to explore differences among 17 independent studies to identify factors that may have contributed to the discrepant findings. This report discusses six putative factors that are grouped into two categories: (a) clinical management criteria: hormone receptor classification, menopausal status, and tamoxifen combination therapy; (b) pharmacologic criteria: genotyping comprehensiveness, CYP2D6 inhibitor coadministration, and tamoxifen adherence. Comparison of these factors between the positive and negative studies suggests that tamoxifen combination therapy, genotyping comprehensiveness, and CYP2D6 inhibitor coadministration may account for some of the contradictory results. Future association studies on the link between CYP2D6 genotype and tamoxifen treatment efficacy should account for combination therapy and CYP2D6 inhibition, and interrogate as many CYP2D6 alleles as possible.

References Powered by Scopus

Tamoxifen for early breast cancer: An overview of the randomised trials

3818Citations
N/AReaders
Get full text

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

2218Citations
N/AReaders
Get full text

Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects

1009Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Addressing phenoconversion: The Achilles' heel of personalized medicine

211Citations
N/AReaders
Get full text

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

139Citations
N/AReaders
Get full text

Cancer pharmacogenomics: Early promise, but concerted effort needed

132Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hertz, D. L., McLeod, H. L., & Irvin, W. J. (2012). Tamoxifen and CYP2D6: A Contradiction of Data. The Oncologist, 17(5), 620–630. https://doi.org/10.1634/theoncologist.2011-0418

Readers over time

‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 22

59%

Researcher 8

22%

Professor / Associate Prof. 5

14%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

35%

Pharmacology, Toxicology and Pharmaceut... 10

29%

Agricultural and Biological Sciences 6

18%

Biochemistry, Genetics and Molecular Bi... 6

18%

Save time finding and organizing research with Mendeley

Sign up for free
0